SCHEMBL18655351

SCHEMBL18655351

CNCCNc1c2ccc3ccccc3c2nc2c1ccc1ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLR1A O95602 1/20 0.44
CYP1A2 P05177 1/20 0.44
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
POLB P06746 5/20 0.40
RAD52 P43351 5/20 0.40
SLC6A4 P31645 3/20 0.40
HRH1 P35367 1/20 0.40
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
RAB9A P51151 2/20 0.39
MITF O75030 1/20 0.39
TTR P02766 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18631798 0.91 POLB (0.49) POLR1ACYP1A2KDM4EALDH1A1MAPT
SCHEMBL18631799 0.79 ACHE (0.44) KDM4EALDH1A1MAPTPOLBKMT2A
SCHEMBL18650739 0.79 L3MBTL1 (0.47) CYP1A2ALDH1A1HPGDMAPTL3MBTL1
SCHEMBL18631802 0.79 ACHE (0.44) KDM4EALDH1A1HPGDMAPTPOLB
SCHEMBL30253677 0.76 POLB (0.66) KDM4EALDH1A1POLBRAD52KMT2A
SCHEMBL617240 0.76 POLB (0.66) KDM4EALDH1A1POLBRAD52KMT2A
SCHEMBL21250745 0.74 RAD52 (0.48) POLR1ACYP1A2KDM4EALDH1A1HPGD
SCHEMBL14388990 0.72 RAD52 (0.75) ALDH1A1POLBRAD52HRH1KMT2A
SCHEMBL18655368 0.72 POLB (0.48) KDM4EALDH1A1MAPTPOLBRAD52
SCHEMBL11668990 0.70 CA12 (0.65) KDM4EALDH1A1HPGDMAPTHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10377784-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith WAKE FOREST UNIVERSITY (US) 2019-08-13 US disclosed
US-10023599-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith WAKE FOREST UNIVERSITY (US) 2018-07-17 US disclosed
US-20170081351-A1 Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith WAKE FOREST UNIVERSITY 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10023599-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith ACR, TP53, MCL1 POLR1A 389/4885CYP1A2 1469/4885KDM4E 4196/4885
US-10377784-B2 Design, synthesis, and biological activity of platinum-benz[c]acridine hybrid agents and methods associated therewith ACR, TP53, BAD POLR1A 428/4885CYP1A2 1417/4885KDM4E 4210/4885
US-20170081351-A1 Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith ACR, TP53, MCL1 POLR1A 389/4885CYP1A2 1469/4885KDM4E 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.